RCKT analyst estimates
Rocket Pharmaceuticals (RCKT) analyst ratings, the average price target and its range, and every firm's latest call.
- 7 firms rate RCKT: 5 buy, 2 hold, 0 sell.
- The average price target is $5.32 from None analysts, from $2.95 to $9.00.
RCKT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 8, 2026 | Goldman Sachs | Rocket Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs | $4.00 |
| Oct 7, 2026 | Jefferies | Rocket Pharmaceuticals (RCKT) PT Lowered to $2.95 at Jefferies | $2.95 |
| Sep 16, 2026 | Needham | Rocket Pharmaceuticals upgraded to Buy from Hold at Needham | $9.00 |
| Jan 8, 2026 | Morgan Stanley | Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley | $5.00 |
| Oct 3, 2025 | Leerink Partners | Rocket Pharmaceuticals price target lowered to $7 from $9 at Leerink | $7.00 |
| May 28, 2025 | Jefferies | These Analysts Slash Their Forecasts On Rocket Pharmaceuticals | $2.50 |
| May 28, 2025 | Goldman Sachs | Goldman downgrades Rocket to Sell on 'surprising and concerning' update | $2.00 |
| Dec 30, 2024 | Wedbush | Rocket Pharmaceuticals initiated with an Outperform at Wedbush | $32.00 |
| Nov 11, 2024 | Canaccord Genuity | Rocket Pharmaceuticals (RCKT) PT Raised to $39 at Canaccord Genuity | $39.00 |
| Sep 18, 2024 | Canaccord Genuity | Canaccord Genuity Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT) | $38.00 |
| Sep 17, 2024 | Morgan Stanley | Morgan Stanley on Rocket Pharmaceuticals (RCKT): 'we are encouraged by rapid enrollment' | $45.00 |
| Apr 2, 2024 | Goldman Sachs | Goldman Sachs Starts Rocket Pharmaceuticals (RCKT) at Neutral, 'Four Potential Launches in Next 2Y but DD Oppy May be Overstated' | $39.00 |
| Oct 3, 2022 | Raymond James | Raymond James Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $34 | $34.00 |
| Aug 9, 2022 | Raymond James | Raymond James Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $24 | $24.00 |
| Aug 12, 2021 | UBS | Rocket Pharmaceuticals (RCKT) PT Lowered to $69 at UBS | $69.00 |